CIGP performed an independent valuation analysis of a Malaysian clinical-stage biopharma company, contributing to its preparation for a planned listing on the New York Stock Exchange (“NYSE”).
 

CIGP was mandated by Medika Natura, a Malaysian pre-revenue, clinical-stage biopharma company, to perform an independent valuation analysis of its pharmaceutical pipeline. The company specializes in the development of supplements and botanical drugs ahead of its listing on the New York Stock Exchange (NYSE).

CIGP’s valuation report was provided for supporting internal management decision-making and facilitating external investors’ due diligence in the context of the company’s pre-IPO capital raising efforts.
 

Comprehensive valuation: Leveraging its pharma expertise and emerging-market insights, CIGP conducted a thorough review of the drug pipeline and business plan for this pre-revenue biopharma firm, applying probability-adjusted modelling, milestone-driven analysis, and peer-comparable benchmarks to deliver a robust independent valuation.

Capital market expertise: CIGP conducted a critical evaluation of the company’s capital plans, incorporating the anticipated pre-IPO fundraising and IPO into the financial modelling to more accurately reflect the future capital structure and financing strategy.